Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

Overview

The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs. Rivaroxaban in newly diagnosed or relapsed and refractory multiple myeloma patients treated with Lenalidomide Dexamethasone (Len-Dex) combination therapy. The pilot feasibility study was conducted in preparation for this randomized controlled trial designed to assess the effect of an intervention.

Description

RithMM is a phase IV, pragmatic, multicenter, open label Canadian trial. The study started with a pilot feasibility phase where 3 centres (London, Ottawa and Halifax) enrolled 34 patients within 12 months. Utilizing a roll-over design, the full RithMM trial will require a total of 304 patients to demonstrate that rivaroxaban 10 mg daily for 6 months is superior to ASA 81 mg daily for 6 months in preventing any thromboembolic events in newly diagnosed myeloma (NDMM) and relapsed/refractory (RRMM) patients on Len-Dex -based therapy. The study will require 8 participating centres in order to be able to achieve our recruitment goal within 12 to 18 months. Patients with NDMM or RRMM receiving Len-Dex based combination therapy with or without combination with other anti-myeloma drugs will be assessed for eligibility to be enrolled in the study. The research team intends to rollover the participants of our feasibility study into this current full randomized control trial comparing the efficacy outcome for the RithMM trial is the overall incidence of cardiovascular events, which includes arterial or venous thromboembolic events.

By conducting this trial, the investigators plan to externally validate the International Myeloma Working Group (IMWG) criteria model for thromboembolic risk by assessing the relevance of measuring pre-specified myeloma and thrombosis activity biomarkers (D-Dimer, beta-2 microglobulin, C-reactive protein (CRP), LDH) at every follow-up visit and their potential association with thromboembolism (TE) risk.

Eligibility

Inclusion Criteria:

• Diagnosis of Multiple Myeloma
• Scheduled to start on Len-Dex therapy
• Be ≥ 18 years of age
• 4. Pre-clinical laboratory must meet the following criteria at enrollment
  1. Platelet count >50 × 109/L
  2. AST <2.5x ULN
  3. ALT <2.5x ULN
  4. Total Bilirubin <2.0 xULN
  5. Creatinine clearance (CrCl) >15mL/min using Cockcroft-Gault Equation
• Able to provide written informed consent

Exclusion Criteria:

1. Major bleeding event within the previous 3 months prior to commencement of Len Dex therapy
2. A history of malignancy (with the exception of MM) within 2 years before randomization or any previously diagnosed malignancy with evidence of residual disease. Patients with a history of basal cell or squamous carcinoma are not excluded.
3. Patient with history of gastric or duodenal ulcer within 2 years
4. Patient on therapeutic anticoagulation for treatment of VTE or ATE, or stroke prevention in non-valvular atrial fibrillation. Patients with a previous history of VTE who are not on any active anticoagulant therapy will not be excluded.
5. Patient on antiplatelet agents due to an absolute indication (e.g.; coronary stent, carotid stent).
6. Patient on single agent lenalidomide
7. Life expectancy less than 3 months as determined by the investigator
8. Unstable medical or psychological condition that would interfere with trial participation, as determined by the investigator
9. Patient not able or not willing to give consent to participate in the study
10. Uncontrolled cardiovascular disease within 6 months prior to enrollment
11. Uncontrolled or poorly controlled diabetes or renal disease
12. Major surgery within 2 weeks before randomization
13. Known allergies, hypersensitivity, or intolerance to any of the study drugs